Calmare Therapeutics (CTTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 01-2004 | 10-2003 | 07-2003 | 04-2003 | 01-2003 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,497 | 2,400 | 1,405 | 434 | 107 |
| Marketable Securities | 100 | 100 | 100 | 1,103 | 1,101 |
| Receivables | 897 | 307 | 957 | 932 | 1,930 |
| TOTAL | $2,647 | $2,986 | $2,737 | $2,754 | $3,402 |
| Non-Current Assets | |||||
| PPE Net | 19 | 24 | 30 | 36 | 40 |
| Investments And Advances | 41 | 41 | 43 | 43 | 131 |
| Intangibles | 116 | 133 | 143 | 665 | 705 |
| TOTAL | $177 | $198 | $216 | $744 | $876 |
| Total Assets | $2,823 | $3,184 | $2,953 | $3,498 | $4,278 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 261 | 483 | 502 | 276 | 221 |
| Accrued Expenses | 825 | 1,186 | 1,281 | 1,294 | 1,583 |
| TOTAL | $1,086 | $1,669 | $1,783 | $1,570 | $1,804 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,086 | $1,669 | $1,783 | $1,570 | $1,804 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 6,244 | 6,201 | N/A | 6,201 | 6,201 |
| Common Shares | 62 | 62 | 62 | 62 | 62 |
| Retained earnings | -25,291 | -25,355 | -25,701 | -24,942 | -24,396 |
| TOTAL | $1,737 | $1,515 | $1,169 | $1,928 | $2,474 |
| Total Liabilities And Equity | $2,823 | $3,184 | $2,953 | $3,498 | $4,278 |